Suppr超能文献

儿童幕上原始神经外胚层肿瘤(S-PNET):辅助强化化疗和超分割加速放疗的前瞻性经验。

Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy.

作者信息

Massimino Maura, Gandola Lorenza, Spreafico Filippo, Luksch Roberto, Collini Paola, Giangaspero Felice, Simonetti Fabio, Casanova Michela, Cefalo Graziella, Pignoli Emanuele, Ferrari Andrea, Terenziani Monica, Podda Marta, Meazza Cristina, Polastri Daniela, Poggi Geraldina, Ravagnani Fernando, Fossati-Bellani Franca

机构信息

Neuro-Oncology Functional Unit, Department of Pediatric Oncology, Istituto Nazionale Tumori, Milan, Italy.

出版信息

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1031-7. doi: 10.1016/j.ijrobp.2005.09.026. Epub 2005 Dec 15.

Abstract

PURPOSE

Supratentorial primitive neuroectodermal tumors (S-PNET) are rare and have a grim prognosis, frequently taking an aggressive course with local relapse and metastatic spread. We report the results of a mono-institutional therapeutic trial.

METHODS AND MATERIALS

We enrolled 15 consecutive patients to preradiation chemotherapy (CT) consisting of high-dose methotrexate, high-dose etoposide, high-dose cyclophosphamide, and high-dose carboplatin, craniospinal irradiation (CSI) with hyperfractionated accelerated radiotherapy (HART) plus focal boost, maintenance with vincristine/lomustine or consolidation with high-dose thiotepa followed by autologous stem-cell rescue.

RESULTS

Median age was 9 years; 7 were male, 8 female. Site of disease was pineal in 3, elsewhere in 12. Six patients were had no evidence of disease after surgery (NED). Of those with evidence of disease after surgery (ED), 2 had central nervous system spread. Of the 9 ED patients, 2 had complete response (CR) and 2 partial response (PR) after CT, 4 stable disease, and 1 progressive disease. Of the 7 ED patients before radiotherapy, 1 had CR, 4 PR, and 2 minor response, thus obtaining a 44% CR + PR after CT and 71% after HART. Because of rapid progression in 2 of the first 5 patients, high-dose thiotepa was systematically adopted after HART in the subsequent 10 patients. Six of 15 patients relapsed (4 locally, 1 locally with dissemination, 1 with dissemination) a mean of 6 months after starting CT, 2 developed second tumors; 5 of 6 relapsers died at a median of 13 months. Three-year progression-free survival, event-free survival, and overall survival were 54%, 34%, and 61%, respectively.

CONCLUSION

Hyperfractionated accelerated RT was the main tool in obtaining responses in S-PNET; introducing the myeloablative phase improved the prognosis (3/10 vs. 3/5 relapses), though the outcome remained unsatisfactory despite the adoption of this intensive treatment.

摘要

目的

幕上原始神经外胚层肿瘤(S-PNET)较为罕见,预后较差,通常病程侵袭性强,易出现局部复发和远处转移。我们报告了一项单中心治疗试验的结果。

方法与材料

我们纳入了15例连续患者,给予放疗前化疗(CT),方案包括大剂量甲氨蝶呤、大剂量依托泊苷、大剂量环磷酰胺和大剂量卡铂,采用超分割加速放疗(HART)联合全脑全脊髓照射(CSI)及局部加量,随后用长春新碱/洛莫司汀维持治疗或用大剂量噻替派巩固治疗,继以自体干细胞救援。

结果

中位年龄为9岁;男性7例,女性8例。病变部位位于松果体区3例,其他部位12例。6例患者术后无疾病证据(NED)。术后有疾病证据(ED)的患者中,2例出现中枢神经系统转移。在9例ED患者中,CT后2例完全缓解(CR),2例部分缓解(PR),4例疾病稳定,1例疾病进展。放疗前的7例ED患者中,1例CR,4例PR,2例轻度缓解,因此CT后CR+PR率为44%,HART后为71%。由于前5例患者中有2例进展迅速,随后的10例患者在HART后系统地采用了大剂量噻替派。15例患者中有6例复发(4例局部复发,1例局部复发伴播散,1例播散),平均在开始CT后6个月复发,2例发生第二肿瘤;6例复发患者中有5例在中位时间13个月时死亡。三年无进展生存率、无事件生存率和总生存率分别为54%、34%和61%。

结论

超分割加速放疗是S-PNET获得缓解的主要手段;引入清髓期改善了预后(复发率3/10 vs. 3/5),尽管采用了这种强化治疗,结果仍不尽人意。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验